Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues

  • Authors:
    • Xiaoxia Liu
    • Lingling Cao
    • Jinsong Ni
    • Ning Liu
    • Xiaoming Zhao
    • Yanfang Wang
    • Lin Zhu
    • Lingyao Wang
    • Jin Wang
    • Ying Yue
    • Yong Cai
    • Jingji Jin
  • View Affiliations

  • Published online on: October 3, 2013     https://doi.org/10.3892/ijo.2013.2124
  • Pages: 1925-1934
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human BCCIP, a protein which interacts with BRCA2 and CDKN1A (Cip1, p21), has been implicated in many cellular processes including cell cycle regulation, DNA recombination and damage repair, telomere maintenance, embryonic development and genomic stability. BCCIP gene expression, which is an important BRCA2 cofactor in tumor suppression, has been identified in some primary cancers. Thus, we investigated the role of BCCIP expression in a large sample of clinically diagnosed primary ovarian cancer, renal cell carcinoma (RCC) and colorectal cancer (CRC) tissues. Using clinically diagnosed frozen primary cancer tissues, quantitative PCR (qPCR), western blot analysis (WB) and immunohistochemical staining (IHC) approaches were used to detect and measure gene expression. Reduced BCCIP gene expression in ovarian cancer, RCC and CRC tissues occurred in 74, 89 and 75% of tissue samples, respectively. qPCR analysis of mRNA expression in 54 ovarian cancer, 50 RCC and 44 CRC samples revealed significant (>2-fold decreased) BCCIP downregulation in 56, 70 and 46% of tissue samples, respectively. Although BCCIP expression in three different tumor tissues decreased, the relationship between BCCIP expression and clinicopathological features of each cancer was distinct. Compared to normal tissues, BCCIP expression in ovarian cancers was significantly downregulated in serous, endometrioid and mucinous carcinomas. Downregulation of BCCIP expression was strongly associated with clear cell RCC (ccRCC) and Fuhrman tumor grading, but significant differences in BCCIP expression between CRC and matched normal tissues occurred only in male CRC tissues (p<0.05) and in tissue with a T4 tumor stage (p<0.01). Thus, BCCIP protein was chiefly reduced in ovarian cancer and RCC tissue samples (p<0.05). BCCIP gene expression was downregulated in human ovarian cancer, RCC and CRC tissues, suggesting a role for the gene in the pathogenesis of these cancers.
View Figures
View References

Related Articles

Journal Cover

December 2013
Volume 43 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, X., Cao, L., Ni, J., Liu, N., Zhao, X., Wang, Y. ... Jin, J. (2013). Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues. International Journal of Oncology, 43, 1925-1934. https://doi.org/10.3892/ijo.2013.2124
MLA
Liu, X., Cao, L., Ni, J., Liu, N., Zhao, X., Wang, Y., Zhu, L., Wang, L., Wang, J., Yue, Y., Cai, Y., Jin, J."Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues". International Journal of Oncology 43.6 (2013): 1925-1934.
Chicago
Liu, X., Cao, L., Ni, J., Liu, N., Zhao, X., Wang, Y., Zhu, L., Wang, L., Wang, J., Yue, Y., Cai, Y., Jin, J."Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues". International Journal of Oncology 43, no. 6 (2013): 1925-1934. https://doi.org/10.3892/ijo.2013.2124